Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study - Wikidata - awgldk - TriplyDB

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

http://www.wikidata.org/entity/Q36730132

about

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis.Poly-omic prediction of complex traits: OmicKriging.Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary a Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH Pharmacogenetics and cardiovascular disease--implications for personalized medicine Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner.SLCO1B1 Polymorphisms and Statin-Induced Myopathy.The Association between KIF6 Single Nucleotide Polymorphism rs20455 and Serum Lipids in Filipino-American Women Pharmacogenomics of lipid-lowering therapies.Lipid-lowing pharmacogenomics in Chinese patients.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Pharmacogenomics, lipid disorders, and treatment options.RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol.Common genetic risk factors for coronary artery disease: new opportunities for prevention?Seventeen years of statin pharmacogenetics: a systematic review.Personalized medicine: Genetic risk prediction of drug response.Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Associations of genetic variants for adult lipid levels with lipid levels in children. The Generation R Study.A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects Genes and cardiovascular risk.Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.A genetic risk score is significantly associated with statin therapy response in the elderly population.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients

P2860

Q28218899-546FEB7D-A364-4803-952F-C25C6D8E0730 Q28258442-22B69C2B-484E-4A33-8930-CCD63E11EFEF Q33648028-9383F9F2-8010-47EB-BB92-414FD07ADBEB Q33686783-E15FDCCF-58EB-4340-A8AB-050CFE44B1D2 Q33812687-15CDF489-1062-4D2C-8FD8-0ADCFD062FA0 Q33948919-6EEC070E-E240-451A-97F7-C074CF1A26C7 Q34395551-80173E71-27B2-4717-BB2F-45C618B2A965 Q34453666-BEB23E56-371D-404B-97F3-36ADC40F8516 Q34756897-05DF92E0-2A71-4CB7-A4AD-9295310F7C1F Q35645239-888EEE3A-59E1-48D8-900C-BDAE48759940 Q35855012-A6093C0D-83B6-47B6-8557-F018495CF2CF Q35981408-4D613D99-A3C2-4E01-92C7-2F0348E726DA Q36152978-F3DD3518-3C6E-412A-ADAD-AAFCB16B36F2 Q36480609-D8A08B19-4DD9-44E1-A90F-DBF4CAFC83D9 Q36485405-5C52624C-D8DC-4BFD-810A-91C21145BDEE Q36974672-1F45D8DE-0434-4094-8D91-0021F7E666FF Q37227150-126787B9-96FE-457A-A02B-143F560CD040 Q37410969-1D79D175-4970-4379-AA80-4504FF5F1C99 Q37576928-5EC7CF60-A45A-471D-B96F-F29CA698C13F Q38112823-16C796F7-2FDC-4E61-B3DC-73D6FD235589 Q38129422-D4CA1CE0-0D81-4838-B68F-595D59E520FD Q38155218-F307DDF1-FF17-43CF-8A7E-8A4A1A2BA058 Q38203774-09D37DF5-E919-4462-AB31-9AC491C983C8 Q38438530-8165F125-A751-44F7-84C1-22F6DD047F35 Q38567857-E51A2844-4F57-4E14-8914-DC4C0BF882B0 Q38670109-53C1F05A-DB26-437E-ACE4-E7745D3C295A Q38756015-332267A7-F929-4455-994D-CDCB0C62E7E7 Q38780996-6E9CD6BA-883F-467B-84C0-03151CFBA443 Q40517874-DE01564B-EAB4-4E48-B253-3D61D6C6ABD3 Q40817564-5241B194-D597-4BF7-9D93-BBBD83F96614 Q42291683-CC46E977-6CE6-457E-AEAB-1A0C906F1B09 Q46302932-B09CB6FD-C213-462F-8404-E633B8981F36 Q47750262-8B55248D-C413-4241-9F41-33B7A18ABDCA Q51272834-63AD4C7A-A8EE-4C0A-B540-ECCC89CF88B3 Q51304354-750BCFB2-4F1D-4B04-8AA0-FD82E5FB5D09 Q54216256-A33852FA-E9BD-4913-8125-A022789337FA Q57796514-8209F12D-5305-4935-A797-473097C86E5A Q58765353-262198B7-419E-4979-B5C2-D0C95F304A25

P2860

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

http://www.wikidata.org/entity/Q36730132

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Impact of common genetic varia ...... in the Heart Protection Study

@ast

Impact of common genetic varia ...... in the Heart Protection Study

@en

type

label

Impact of common genetic varia ...... in the Heart Protection Study

@ast

Impact of common genetic varia ...... in the Heart Protection Study

@en

prefLabel

Impact of common genetic varia ...... in the Heart Protection Study

@ast

Impact of common genetic varia ...... in the Heart Protection Study

@en

P1433

Q36730132-23FE42DC-ED45-4711-8A34-DAD5155E3E9F

P1476

Q36730132-EE73E715-34B0-4424-B50B-50AF2A30BBE4

P2093

Q36730132-3EEFE1B3-979D-441B-A462-81C88D822239

Q36730132-5CDCEFBF-E34E-4534-87C3-C7CDFFF88B33

Q36730132-808BCE1B-2431-4A66-ABC1-6EF89ACD8F8F

Q36730132-B42593CC-DABD-4396-B322-8F0152418194

Q36730132-C8739A77-97B9-4A7A-BF1C-136D87A3E49B

Q36730132-DEE19957-F025-41E5-B5B6-F908C8BE979C

Q36730132-F43D94A4-223D-466A-9895-E426019C5FD3

P2860

Q36730132-0901F0F3-B722-4FC5-B462-35B7A3EEEE95

Q36730132-1721CC49-9D65-490D-BC09-45083591ECFE

Q36730132-1CB511AB-8589-45AA-B7C4-A1E2D2FD51E8

Q36730132-2AB8AA03-74F2-4914-85FD-6635EF55B7EE

Q36730132-2F84B2D6-7E84-40E6-9A42-FD926A351C7C

Q36730132-40FF44EB-5B83-41C7-B981-F9752B0645B6

Q36730132-45B415C6-1F31-4603-AA69-2C0E8A191C0A

Q36730132-509BBB4D-F397-42D9-8F87-E1D02AF5F77C

Q36730132-559F59CE-8C0E-4195-BE41-89F65E349A35

Q36730132-5A70128D-5410-48BA-A235-CC35B9AD1D2F

P304

Q36730132-864C23A0-68D6-4FBE-B391-4BB2F535F226

P31

Q36730132-6A17665A-6D5B-4754-8E12-048B45F7D16B

P356

Q36730132-005EC4EE-6960-4E40-B3E1-EDF85A78A007

P433

Q36730132-2B03270A-D038-4C5A-AA2E-CB8A984939C0

P478

Q36730132-DF3C83BF-5698-459B-AF25-8D47FD103BCE

P50

Q36730132-AEA72202-1F43-45BB-A3C5-5C121BAF3571

Q36730132-ECB3A628-1AFF-4127-ACA7-D9B99C868AD1

P577

Q36730132-755335F8-CDA9-412B-B738-D97CB094961F

P5875

Q36730132-5A8C06FB-E8B8-4137-9804-E8880DB5186D

P698

Q36730132-6F03AFD1-9D00-4D0A-9FAD-8E5E7ED999D4

P921

Q36730132-5392AB70-B830-480E-8581-BD4FA98CDA9A

P932

Q36730132-A02F43E8-0E8E-4AD2-993C-7DA4A0BF9CC4

P356

P1433

European Heart Journal

P1476

Impact of common genetic varia ...... in the Heart Protection Study

@en

P2093

Alison Offer

http://www.w3.org/2001/XMLSchema#string

Emma Link

http://www.w3.org/2001/XMLSchema#string

Jane Armitage

http://www.w3.org/2001/XMLSchema#string

Jemma C Hopewell

http://www.w3.org/2001/XMLSchema#string

MRC/BHF Heart Protection Study Collaborative Group

http://www.w3.org/2001/XMLSchema#string

Robert Clarke

http://www.w3.org/2001/XMLSchema#string

Rory Collins

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association of lipid-lowering response to statins in combined study populations

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men

Biological, clinical and population relevance of 95 loci for blood lipids

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.

A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population

P304

982-992

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHS344

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232705828

http://www.w3.org/2001/XMLSchema#string

P698

23100282

http://www.w3.org/2001/XMLSchema#string

P921

response to simvastatin

P932

3612775

http://www.w3.org/2001/XMLSchema#string